Loading...

XLO XILIO THERAPEUTICS INC Management Changes 8-K Filing

XL T

XL

XILIO THERAPEUTICS INC

(XLO)

2023 8-K

Stock Option Update

Financial Results Announced

New Clinical Data

Stock Listing Change

Clinical Trial Update

NASDAQ Compliance Issue

Financial Results

Equity Offerings

Product Expansion

Financial Statements

Financial Results

Collaboration Agreement

Investor Update

Stock Sale Agreement

Q3 2024 Results

Financial Results Announcement

Annual Meeting Results

Board Expansion and Directo...

Financial Results Announcement

Financial Results Announcement

Stock Purchase Agreement wi...

License Agreement with Gilead

Equity Awards Granted to Ex...

Phase 1 Clinical Trial Data...

Financial Results Announcement

Financial Results and Inves...

Appointment of Chief Operat...

Annual Meeting of Stockholders

Presentation and Clinical T...

Financial Results Announcement

Appointment of Principal Fi...

Financial Results Announcement

Investor Conferences

External Links:

Xilio Therapeutics, Inc. appointed Christopher Frankenfield as Chief Operating Officer, with an annualized base salary of $500,000 and an option to purchase 150,000 shares of the company's common stock.

AI Assistant

XILIO THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.